Cargando…
Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies
Immunocompromised individuals, including multiple sclerosis (MS) patients on certain immunotherapy treatments, are considered susceptible to complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific vaccination regimens have been recommended for suitable...
Autores principales: | Alfonso-Dunn, Roberto, Lin, Jerry, Kirschner, Vanessa, Lei, Joyce, Feuer, Grant, Malin, Michaela, Liu, Jiayuan, Roche, Morgan, Sadiq, Saud A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388928/ https://www.ncbi.nlm.nih.gov/pubmed/35990701 http://dx.doi.org/10.3389/fimmu.2022.926318 |
Ejemplares similares
-
Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study
por: Alfonso-Dunn, Roberto, et al.
Publicado: (2023) -
Cerebral organoids in primary progressive multiple sclerosis reveal stem cell and oligodendrocyte differentiation defect
por: Daviaud, Nicolas, et al.
Publicado: (2023) -
Pre-Transplant Donor-Specific T-Cell Alloreactivity Is Strongly Associated with Early Acute Cellular Rejection in Kidney Transplant Recipients Not Receiving T-Cell Depleting Induction Therapy
por: Crespo, Elena, et al.
Publicado: (2015) -
Antibody-mediated cell depletion therapies in multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022) -
Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status
por: Harris, Violaine K., et al.
Publicado: (2014)